Will release its fourth-quarter and year-end 2023 financial results on Thursday, March 21, prior to ...
Announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. ...
Has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc., a biopharmaceutical ...
Reported financial results for its third quarter ended September 30, 2023. All currency amounts are ...
Has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). ...
Reported financial results for its second quarter ended June 30, 2023. Revenues were $89.905 million, ...
Announced today acceptance by the Toronto Stock Exchange of the Company's Notice of Intention to Make ...
Will release its third-quarter 2022 financial results on Thursday, November 10, prior to market opening. ...
Announced it placed No. 22 on the 2022 Report on Business ranking of Canada’s Top Growing Companies. ...
Reported financial results for its second quarter ended June 30, 2022. Revenues were $75,820, an increase ...